Fortitude Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Fortitude Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-71	Closed	-$50K	–	1024
2022 Q1	$50K	Hold	71	–	–	0.03%	527
2021 Q4	$45K	Buy	+71	New	+$43.7K	0.02%	579

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fortitude Advisory Group's REGN Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 71 shares — an estimated $50K sold.

Fortitude Advisory Group first reported a position in REGN in Q4 2021 and held it in 2 quarters. The position peaked at $50K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Fortitude Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Fortitude Advisory Group sold 71 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $50K.
Fortitude Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Fortitude Advisory Group's Regeneron Pharmaceuticals position peaked at $50K in Q1 2022.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.